BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:XmAb942 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of XmAb942\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06619990-69@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:XmAb942: Phase 1/2 readout est. (NCT06619990)
DESCRIPTION:XmAb942\, phase 1/2\, Ulcerative Colitis.\nStudy: Study of XmAb
 942 in Healthy Participants and Participants With Ulcerative Colitis\nEsti
 mated primary completion: December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/xmab942#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06619990
URL:https://assetmemo.bio/drug/xmab942#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
